TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Files An 8-K Other Events
Item 8.01

Tonix Pharmaceuticals Holding Corp. Exhibit
EX-99.01 2 ex99-01.htm PRESS RELEASE   Tonix Pharmaceuticals Holding Corp. 8-K   Exhibit 99.01   Tonix Pharmaceuticals Enters into Research and Exclusive License Option Agreement with Kansas State University to Develop Vaccine Against COVID-19   Research to Develop Live Replicating Vaccine (TNX-2300) to Protect Against COVID-19 Based on Bovine Parainfluenza Virus   TNX-2300 Will Be Tonix’s Second Live Replicating Virus Vaccine Platform   TNX-2300 Is Designed to Utilize the CD40-Ligand to Drive T cell Immunity NEW YORK,…
To view the full exhibit click here